Ramipril
Ramipril is an ACE inhibitor used to treat high blood pressure, lower the risk of heart attack, stroke and cardiovascular death in certain high-risk adults, and treat heart failure after a heart attack.
🧬 Where this information comes from Click to expand
The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 42 clinical label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →
Ramipril is an ACE inhibitor, on the market since about 1991 and available as a generic, that relaxes blood vessels; it is a common first choice for high blood pressure and also lowers the risk of heart attack and stroke in certain high-risk adults and treats heart failure after a heart attack. Most people tolerate it well; dizziness early on and a nagging dry cough are what they notice. Its boxed warning is about pregnancy, because it can injure or kill a developing baby, so it should be stopped as soon as pregnancy is known. Swelling of the face, lips, tongue or throat (angioedema) needs emergency help.
Clinical pearls
- Skip ibuprofen, naproxen and other NSAIDs unless your pharmacist okays them; they can strain the kidneys and blunt ramipril’s effect.
- Avoid potassium supplements and potassium salt substitutes, and expect blood tests for potassium and kidney function along the way.
- A dry, tickly cough that lingers is a known ACE inhibitor effect, and switching to a related medicine usually ends it.
- If swallowing is hard, the capsule can be opened onto applesauce or into water or apple juice; take the whole mixture.
⚠️ FDA Boxed Warning — the FDA’s strongest safety alert ▾
Do not take ramipril during pregnancy. Drugs like ramipril, which act on the renin-angiotensin system, can injure or kill a developing baby. This risk is mainly seen in the second and third trimesters, and can include reduced fetal kidney function, low amniotic fluid, lung and skull problems, and death. If you find out you are pregnant, contact your doctor right away so ramipril can be stopped as soon as possible.
Patient information guide A plain-language walkthrough of Ramipril, written from its FDA label.
What Ramipril is used for
▾
Ramipril is an ACE inhibitor with these labeled uses for ramipril capsules:
- Treating high blood pressure, alone or with thiazide diuretics
- Reducing the risk of heart attack, stroke or cardiovascular death in patients 55 or older at high risk (for example, with coronary artery disease, stroke, peripheral vascular disease, or diabetes plus another risk factor)
- Treating stable patients with signs of congestive heart failure within the first few days after a heart attack
How Ramipril works
▾
Ramipril is converted in the body to ramiprilat, its active form. Ramiprilat blocks ACE, the enzyme that makes angiotensin II. Angiotensin II narrows blood vessels and prompts the body to release aldosterone.
With less angiotensin II, blood vessels relax and blood pressure falls. Lower aldosterone can also cause a small rise in potassium.
Ramipril dosage
▾
Ramipril capsules are taken by mouth, once or twice daily depending on the condition. Treatment often starts low and is raised gradually. Food does not significantly change how much is absorbed.
- Swallow capsules whole in general.
- Or open the capsule and mix the contents into about 4 oz of applesauce, water or apple juice, and consume all of it.
- Kidney problems, dehydration or diuretic use may call for a lower starting dose.
- After the first dose for heart failure after a heart attack, you are observed for a period.
Follow your prescriber’s directions and the label.
Dosing details from the FDA-approved label
From the Ramipril prescribing information (“Dosage and Administration”). Doses are set by your prescriber for your product, condition, kidney function and age — never change a dose on your own.
- Hypertension
- Initial dose is 2.5 mg to 20 mg once daily
- Recommended initial dose for patients not receiving a diuretic is 2.5 mg once a day
- Adjust dosage according to blood pressure response after 2 to 4 weeks of treatment
- Usual maintenance dosage is 2.5 mg to 20 mg daily as a single dose or in two equally divided doses
- If blood pressure is not controlled with ramipril alone, a diuretic can be added; if antihypertensive effect diminishes toward the end of the dosing interval with once daily dosing, consider an increase in dosage or twice daily administration
- Reduction in the risk of myocardial infarction, stroke, or death from cardiovascular causes
- 2.5 mg once daily for 1 week, 5 mg once daily for the next 3 weeks, then increased as tolerated to a maintenance dose of 10 mg once daily
- If the patient is hypertensive or recently post-myocardial infarction, can also be given as a divided dose
- Heart failure post-myocardial infarction
- Starting dose of 2.5 mg twice daily (5 mg per day)
- If patient becomes hypotensive, decrease to 1.25 mg twice daily
- After one week at the starting dose, increase if tolerated toward a target dose of 5 mg twice daily, with dosage increases about 3 weeks apart
- Observe patient under medical supervision for at least two hours and until blood pressure has stabilized for at least an additional hour after the initial dose; if possible reduce dose of any concomitant diuretic
- Hypertension with renal impairment (creatinine clearance not >40 mL/min)
- Recommended initial dose is 1.25 mg once daily
- May be titrated upward until blood pressure is controlled
- Maximum: Maximum total daily dose of 5 mg
- In patients with estimated creatinine clearance >40 mL/min usual regimens may be followed; with worse impairment, 25% of the usual dose is expected to produce full therapeutic levels of ramiprilat
- Heart failure post-myocardial infarction with renal impairment
- Recommended initial dose is 1.25 mg once daily
- May be increased to 1.25 mg twice daily, and up to a maximum dose of 2.5 mg twice daily depending on clinical response and tolerability
- Maximum: 2.5 mg twice daily
- Applies to patients with worse renal impairment than creatinine clearance >40 mL/min
- Volume depletion or renal artery stenosis
- Initiate dosing at 1.25 mg once daily
- Adjust dosage according to blood pressure response
- Applies if volume depletion (e.g., past and current diuretic use) or renal artery stenosis is suspected
Read the label’s full dosing text
2 DOSAGE AND ADMINISTRATIO Hypertension: Initial dose is 2.5 mg to 20 mg once daily. Adjust dosage according to blood pressure response after 2 to 4 weeks of treatment. The usual maintenance dose following titration is 2.5 mg to 20 mg daily as a single dose or equally divided doses ( 2.1 ). Reduction in the risk of myocardial infarction, stroke, or death from cardiovascular causes: 2.5 mg once daily for 1 week, 5 mg once daily for 3 weeks, and increased as tolerated to a maintenance dose of 10 mg once daily (2.2). Heart failure post-myocardial infarction: Starting dose of 2.5 mg twice daily. If patient becomes hypotensive at this dose, decrease dosage to 1.25 mg twice daily. Increase dose as tolerated toward a target dose of 5 mg twice daily, with dosage increases about 3 weeks apart (2.3). Dosage adjustment: See respective sections pertaining to dosage adjustment in special situations ( 2.5 ). 2.1 Hypertension The recommended initial dose for patients not receiving a diuretic is 2.5 mg once a day. Adjust dose according to blood pressure response. The usual maintenance dosage range is 2.5 mg to 20 mg per day administered as a single dose or in two equally divided doses. In some patients treated once daily, the antihypertensive effect may diminish toward the end of the dosing interval. In such patients, consider an increase in dosage or twice daily administration. If blood pressure is not controlled with ramipril capsules alone, a diuretic can be added. 2.2 Reduction in Risk of Myocardial Infarction, Stroke, and Death from Cardiovascular Causes Initiate dosing at 2.5 mg once daily for 1 week, 5 mg once daily for the next 3 weeks, and then increase as tolerated, to a maintenance dose of 10 mg once daily. If the patient is hypertensive or recently post-myocardial infarction, ramipril capsules can also be given as a divided dose. 2.3 Heart Failure Post-Myocardial Infarction For the treatment of post-myocardial infarction patients who have shown signs of congestive heart failure, the recommended starting dose of ramipril capsules is 2.5 mg twice daily (5 mg per day). A patient who becomes hypotensive at this dose may be switched to 1.25 mg twice daily. After one week at the starting dose, increase dose (if tolerated) toward a target dose of 5 mg twice daily, with dosage increases being about 3 weeks apart.
Excerpted — the section continues on the label. Read the full Dosage and Administration section on DailyMed →
Ramipril side effects
▾
The most common side effects are:
Common side effects
- Headache
- Dizziness
- Fatigue or weakness
- Persistent dry cough
- Low blood pressure (more often after a heart attack)
- Nausea or vomiting
When to get medical help
- Swelling of the face, lips, tongue or throat, or trouble breathing: stop the drug and get emergency help, as this angioedema can be fatal.
- Severe belly pain with or without nausea or vomiting, which can be intestinal angioedema.
- Yellowing of the skin or eyes (jaundice), which can signal rare serious liver problems.
- Fainting or severe lightheadedness from very low blood pressure.
- Signs of infection, such as fever or sore throat, since rare drops in white blood cells can occur.
- Becoming pregnant while taking it: call your doctor right away.
Ramipril warnings and precautions
▾
- Pregnancy: can cause fetal injury and death; stop as soon as pregnancy is detected.
- Angioedema: serious swelling that can block the airway.
- Low blood pressure: most likely with dehydration, salt restriction, dialysis or diuretics.
- Kidney changes and high potassium: monitoring may be needed.
- Rare: liver failure starting with jaundice, and low white blood cell counts.
- Cough: persistent dry cough can occur and resolves after stopping.
Ramipril interactions
▾
These can clash with ramipril:
- Diuretics: excessive blood pressure drop
- Potassium supplements, salt substitutes, potassium-sparing diuretics: high potassium
- ARBs, other ACE inhibitors, aliskiren: more low blood pressure, high potassium and kidney problems
- Sacubitril/valsartan: contraindicated; wait 36 hours when switching
- NSAIDs: kidney harm and weaker blood pressure effect
- Lithium: possible lithium toxicity
- mTOR inhibitors: higher angioedema risk
- Injectable gold: rare flushing and low blood pressure reactions
Interactions listed in the FDA-approved label
From the Ramipril prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.
- Diuretics: Patients on diuretics, especially if recently instituted, may occasionally experience an excessive reduction of blood pressure after starting ramipril. Decrease or discontinue the diuretic or increase salt intake prior to starting ramipril; if not possible, reduce the starting dose.
- Agents increasing serum potassium: Coadministration with other drugs that raise serum potassium levels may result in hyperkalemia. Monitor serum potassium.
- Other agents affecting RAS (RAS inhibitors, aliskiren): Combined use of RAS inhibitors is generally to be avoided. Do not co-administer aliskiren with ramipril in patients with diabetes.
- Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported with ACE inhibitors; if a diuretic is also used, the risk of lithium toxicity may be increased. Frequent monitoring of serum lithium levels is recommended.
- Gold (injectable sodium aurothiomalate): Nitritoid reactions (facial flushing, nausea, vomiting and hypotension) have been reported rarely with injectable gold and concomitant ACE inhibitor therapy including ramipril.
- NSAIDs including selective COX-2 inhibitors: In elderly, volume-depleted or renally compromised patients, co-administration may result in deterioration of renal function, including possible acute renal failure, usually reversible; the antihypertensive effect of ramipril may be attenuated. Monitor renal function periodically.
- mTOR inhibitors (e.g. temsirolimus) or neprilysin inhibitors: Patients taking concomitant therapy may be at increased risk for angioedema.
Read the label’s full interactions text
7 DRUG INTERACTIONS Diuretics: Possibility of excessive hypotension ( 7.1 ). Lithium: Use with caution (7.4). Gold: Nitritoid reactions have been reported (7.5). NSAIDS use may lead to increased risk of renal impairment and loss of antihypertensive effect (7.6). mTOR inhibitor or neprilysin inhibitor use may increase angioedema risk (7.7). 7.1 Diuretics Patients on diuretics, especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with ramipril. The possibility of hypotensive effects with ramipril can be minimized by either decreasing or discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with ramipril. If this is not possible, reduce the starting dose [ see Dosage and Administration ( 2 ) ]. 7.2 Agents Increasing Serum Potassium Coadministration of ramipril with other drugs that raise serum potassium levels may result in hyperkalemia. Monitor serum potassium in such patients. 7.3 Other Agents Affecting RAS In general, avoid combined use of RAS inhibitors. [see Warnings and Precautions (5.7) ] . Do not co-administer aliskiren with Ramipril in patients with diabetes [see Contraindications (4) ] . 7.4 Lithium Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium; therefore, frequent monitoring of serum lithium levels is recommended. If a diuretic is also used, the risk of lithium toxicity may be increased. 7.5 Gold Nitritoid reactions (symptoms include facial flushing, nausea, vomiting and hypotension) have been reported rarely in patients on therapy with injectable gold (sodium aurothiomalate) and concomitant ACE inhibitor therapy including ramipril.
Excerpted — the section continues on the label. Read the full Drug Interactions section on DailyMed →
Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.
Before taking Ramipril
▾
- Do not use if allergic to ramipril or another ACE inhibitor, or after angioedema with one.
- Do not use with sacubitril/valsartan, or with aliskiren if you have diabetes.
- Tell your doctor if you are pregnant or may become pregnant.
- Not recommended while breastfeeding.
- Not established as safe and effective in children.
- Older adults: some may be more sensitive.
- Kidney or liver disease: dosing or monitoring may change.
Ramipril overdose
▾
The most likely sign of too much ramipril is low blood pressure. Treatment is supportive, such as an infusion of saline. If you suspect an overdose, get medical help right away.
What Ramipril does in the body
▾
Ramipril strongly reduces ACE activity. With repeated doses, ACE activity falls by more than 90% four hours after a dose, and over 80% inhibition remains at 24 hours. This long effect supports once-daily dosing for many people.
How your body processes Ramipril
▾
Ramipril is absorbed within about an hour and is converted mainly in the liver to its active form, ramiprilat, which peaks 2 to 4 hours after a dose. Food slows absorption but does not significantly change how much is absorbed. About 60% is cleared through urine and 40% in feces. Kidney impairment causes ramiprilat to build up, and liver impairment slows its conversion.
How to store Ramipril
▾
Store at 20 o C to 25 o C (68 o F to 77 o F) . Dispense in a tight, light-resistant container with child-resistant closure.
Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →
Supplements & herbs that interact with Ramipril
149 supplements and herbal products have documented interactions with Ramipril in the licensed clinical database we use. Most are manageable — but your pharmacist should know about everything you take, including vitamins and herbals.
- Major · 6
- Moderate · 119
- Minor · 24
Educational information from a licensed clinical database (Natural Medicines) — see our data sources & update cadence. Not medical advice: an interaction being documented does not mean it will happen to you; do not start or stop medications or supplements without professional guidance.
Nutrient depletion considerations
Ramipril has been associated with lower levels of 1 nutrient in the clinical literature. This does not mean a deficiency will occur — it means these may be worth discussing with your pharmacist or healthcare provider, especially with long-term use.
Educational information from a licensed clinical database (Natural Medicines) — not medical advice. Do not start or stop medications or supplements without professional guidance.
Ramipril: pharmacist answers to common questions
Quick, plain-English answers to the questions patients ask most about Ramipril — the kind of thing our pharmacy team would talk through with you at the counter.
What is ramipril for?
▾
How should I take my capsules?
▾
What side effects should I expect?
▾
When should I get urgent help?
▾
Can I take ibuprofen or potassium with it?
▾
What if I become pregnant?
▾
Is Ramipril available over the counter?
▾
When was Ramipril first available?
▾
Who makes Ramipril?
▾
Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →
More about Ramipril on HelloPharmacist
Ramipril forms and strengths (how it comes)
Ramipril is available in 1 form. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.
Capsule
How this form is used
- Ramipril capsules treat high blood pressure, alone or with thiazide diuretics.
- Ramipril capsules lower the risk of heart attack, stroke and cardiovascular death in high-risk patients 55 or older.
- Ramipril capsules treat heart failure signs after a heart attack in stable patients.
- Ramipril capsules are generally swallowed whole.
- Ramipril capsules can be opened and sprinkled on applesauce or mixed in water or apple juice; consume all of the mixture.
- Prepared Ramipril capsule mixtures can be stored up to 24 hours at room temperature or 48 hours refrigerated.
Ramipril on the U.S. market: products, makers and brands
How Ramipril appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.
17 companies list 69 Ramipril product records with the FDA, mostly as capsule; the earliest marketing or approval year on record is 1991. Brand names on the directory include Altace, Vostally; the rest are generics.
Also listed with the FDA, not a patient dose form: Powder (9) — bulk drug substance sold to compounders/manufacturers and multi-item kits. These aren’t counted in the dose-form total above.
Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
How widely Ramipril is used (Medicaid data)
A general measure of how commonly Ramipril is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.
Think of this as a proxy for how widely Ramipril is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.
How commonly is Ramipril prescribed? Of the 1,601 medications we measure, Ramipril ranks #586 by Medicaid prescriptions — more than 63% of them.
Utilization by Ramipril product
Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.
ramipril 10 MG Oral Capsule Most dispensed
Summed across the 9 of 107 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 261962
ramipril 5 MG Oral Capsule
Summed across the 10 of 101 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 198189
ramipril 2.5 MG Oral Capsule
Summed across the 8 of 84 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 198188
ramipril 1.25 MG Oral Capsule
Summed across the 5 of 48 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 845488
Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.
Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Ramipril, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 32 of 340 listed Ramipril NDCs with Medicaid activity.
Compare Ramipril products
A representative set of FDA-listed product records for Ramipril — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)
| Strength | Route | Manufacturer / Labeler | Category ⓘ | Details |
|---|---|---|---|---|
| 💊Capsule | ||||
| 2.5 mg | Oral | A-S Medication Solutions × 2 listings | ANDA | View NDC → |
| 5 mg | Oral | A-S Medication Solutions | ANDA | View NDC → |
| 10 mg | Oral | A-S Medication Solutions × 4 listings | ANDA | View NDC → |
| 1.25 mg | Oral | Aurobindo Pharma Limited | ANDA | View NDC → |
| 2.5 mg | Oral | Aurobindo Pharma Limited | ANDA | View NDC → |
| 5 mg | Oral | Aurobindo Pharma Limited | ANDA | View NDC → |
| 10 mg | Oral | Aurobindo Pharma Limited | ANDA | View NDC → |
| 1.25 mg | Oral | BluePoint Laboratories | ANDA | View NDC → |
| 2.5 mg | Oral | BluePoint Laboratories | ANDA | View NDC → |
| 5 mg | Oral | BluePoint Laboratories | ANDA | View NDC → |
| 10 mg | Oral | BluePoint Laboratories | ANDA | View NDC → |
| 2.5 mg | Oral | Bryant Ranch Prepack | ANDA | View NDC → |
| 5 mg | Oral | Bryant Ranch Prepack × 3 listings | ANDA | View NDC → |
| 10 mg | Oral | Bryant Ranch Prepack | ANDA | View NDC → |
| 1.25 mg | Oral | Chartwell RX, LLC. | ANDA | View NDC → |
| 2.5 mg | Oral | Chartwell RX, LLC. | ANDA | View NDC → |
| 5 mg | Oral | Chartwell RX, LLC. | ANDA | View NDC → |
| 10 mg | Oral | Chartwell RX, LLC. | ANDA | View NDC → |
| 1.25 mg | Oral | Exelan Pharmaceuticals, Inc. | ANDA | View NDC → |
| 2.5 mg | Oral | Exelan Pharmaceuticals, Inc. | ANDA | View NDC → |
| 5 mg | Oral | Exelan Pharmaceuticals, Inc. | ANDA | View NDC → |
| 10 mg | Oral | Exelan Pharmaceuticals, Inc. | ANDA | View NDC → |
| 2.5 mg | Oral | GSMS, Incorporated | ANDA | View NDC → |
| 5 mg | Oral | GSMS, Incorporated | ANDA | View NDC → |
| 10 mg | Oral | GSMS, Incorporated | ANDA | View NDC → |
| 1.25 mg | Oral | Hikma Pharmaceuticals USA Inc. | ANDA | View NDC → |
| 2.5 mg | Oral | Hikma Pharmaceuticals USA Inc. | ANDA | View NDC → |
| 5 mg | Oral | Hikma Pharmaceuticals USA Inc. | ANDA | View NDC → |
| 10 mg | Oral | Hikma Pharmaceuticals USA Inc. | ANDA | View NDC → |
| 1.25 mg | Oral | Lupin Pharmaceuticals, Inc. | ANDA | View label ↗ |
| 2.5 mg | Oral | Lupin Pharmaceuticals, Inc. | ANDA | View NDC → |
| 5 mg | Oral | Lupin Pharmaceuticals, Inc. | ANDA | View NDC → |
| 10 mg | Oral | Lupin Pharmaceuticals, Inc. | ANDA | View NDC → |
| 2.5 mg | Oral | Northwind Health Company, LLC × 2 listings | ANDA | View NDC → |
| 5 mg | Oral | Northwind Health Company, LLC × 2 listings | ANDA | View NDC → |
| 10 mg | Oral | Northwind Health Company, LLC × 3 listings | ANDA | View NDC → |
| 10 mg | Oral | NuCare Pharmaceuticals, Inc. | ANDA | View NDC → |
| 2.5 mg | Oral | PD-Rx Pharmaceuticals, Inc. | ANDA | View NDC → |
| 2.5 mg | Oral | Proficient Rx LP × 2 listings | ANDA | View NDC → |
| 5 mg | Oral | Proficient Rx LP | ANDA | View NDC → |
| 10 mg | Oral | Proficient Rx LP × 3 listings | ANDA | View NDC → |
| 2.5 mg | Oral | Remedyrepack Inc. | ANDA | View NDC → |
| 5 mg | Oral | Remedyrepack Inc. | ANDA | View NDC → |
| 10 mg | Oral | Remedyrepack Inc. | ANDA | View NDC → |
| 1.25 mg | Oral | Rising Pharma Holdings, Inc. | ANDA | View NDC → |
| 2.5 mg | Oral | Rising Pharma Holdings, Inc. | ANDA | View NDC → |
| 5 mg | Oral | Rising Pharma Holdings, Inc. | ANDA | View NDC → |
| 10 mg | Oral | Rising Pharma Holdings, Inc. | ANDA | View NDC → |
| 1.25 mg | Oral | Zydus Lifesciences Limited | ANDA | View NDC → |
| 2.5 mg | Oral | Zydus Lifesciences Limited | ANDA | View NDC → |
| 5 mg | Oral | Zydus Lifesciences Limited | ANDA | View NDC → |
| 10 mg | Oral | Zydus Lifesciences Limited | ANDA | View NDC → |
| 1.25 mg | Oral | Zydus Pharmaceuticals USA Inc. | ANDA | View NDC → |
| 2.5 mg | Oral | Zydus Pharmaceuticals USA Inc. | ANDA | View NDC → |
| 5 mg | Oral | Zydus Pharmaceuticals USA Inc. | ANDA | View NDC → |
| 10 mg | Oral | Zydus Pharmaceuticals USA Inc. | ANDA | View NDC → |
Showing 69 of 69 products — FDA National Drug Code Directory. See every product, package size and price: browse all 69 Ramipril NDCs →
Ramipril side effects reported to the FDA (FAERS)
After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Ramipril — a signal of what to watch for, not proof the drug caused it.
Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Ramipril in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.
Ramipril FDA approval history
How Ramipril went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.
Source: Drugs@FDA.
Ramipril recall history
A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.
The FDA’s enforcement reports list 2 Ramipril recalls since July 2021, covering 4 product listings. One of them is still ongoing and is listed first. A recall names specific lots from one company, so check the lot number on your own bottle rather than assuming every product is affected; your pharmacist can check whether your supply came from an affected lot.
- Ramipril Capsules USP, 10 mg, packaged in a) 100 Capsules (NDC 76282-673-01) and b) 500 Capsules (NDC 76282-673-05) bottles, Rx only, Manufactured for: Exelan Pharmaceuticals, Inc., Boca Raton, FL 33… Lots: a) Lot #: AC5470A, Exp. Date July 2027 b) Lot #: AC5470B, Exp. Date July 2027 FDA record D-0831-2026 →
- Ramipril Capsules USP 10 mg, a) 90 count (NDC 68180-591-09), b) 100 count NDC 68180-591-01), and c) 500 count (NDC 68180-591-02) bottles, Rx only, Manufactured for Lupin Pharmaceuticals, Inc., Baltim… Lots: a) NDC 68180-591-09; Lots G327086, exp. date 30-Sep-25 GA01065, exp. date 31-Dec-25, b) NDC 68180-591-01 Lots G325033, G324987, exp. date 31-Jul-25, G325110, GA00956, GA01066, GA01126, exp. date 31-Dec-25, GA03299, GA03288, GA03287, exp. d… FDA record D-0054-2025 →
- Ramipril Capsules USP 5 mg, a) 90 count (NDC 68180-590-09), b) 100 count NDC 68180-590-01), and c) 500 count (NDC 68180-590-02) bottles, Rx only, Manufactured for Lupin Pharmaceuticals, Inc., Baltimo… Lots: a) NDC 68180-590-09; Lots G326928, exp. date 30-Sep-25, GA00964, exp. date 31-Dec-25, b) NDC 68180-590-01, Lots G326897, G326929, exp. date 30-Sep-25, GA00854, GA00933, GA00954, exp. date 31-Dec-25, c) NDC 68180-590-02, Lot GA00955, exp. d… FDA record D-0053-2025 →
- Ramipril Capsules USP 2.5 mg, a) 90 count (NDC 68180-589-09), b) 100 count NDC 68180-589-01), and c) 500 count (NDC 68180-589-02) bottles, Rx only, Manufactured for Lupin Pharmaceuticals, Inc., Balti… Lots: a) NDC 68180-589-09; Lots G326781, exp. date 30-Sep-25, GA04468, exp. date 31-May-25 b) NDC 68180-589-01; Lots G326763, exp. date 30-Sep-25, GA03041, exp. date 31-Mar-26, GA03725, exp. date 30-Apr-26, GA04402, exp. date 31-May-26, c) NDC 6… FDA record D-0052-2025 →
Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Sep 24, 2026.
RxNorm Concept Web — From Ingredient to Every Form and Strength
This page starts with one ingredient concept (IN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). Combination products remain separate concepts with their own pages.
RxCUI 35296 3 dose forms · 9 strengths
-
Dose form (SCDF) Oral Capsule RxCUI 373748In current FDA listings -
Dose form (SCDF) Oral Solution RxCUI 2727323No current FDA listingClinical drug / strength (SCD) 1 MG/MLRxCUI 2727324 -
Dose form (SCDF) Oral Tablet RxCUI 373749No current FDA listingClinical drug / strength (SCD) 1.25 MGRxCUI 4019652.5 MGRxCUI 2518565 MGRxCUI 25185710 MGRxCUI 401968
Look up RxCUI 35296 in the RxCUI Atlas →
RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.
Ramipril supply and shortage status
Whether Ramipril is in short supply in the U.S. right now, plus any shortage history the FDA has on record. A shortage usually reflects a manufacturing or demand issue — not a safety problem with the drug.
Source: openFDA, from the FDA Drug Shortages database.
💵 What Ramipril costs pharmacies (NADAC benchmark)
The national average invoice price pharmacies pay for the drug itself, from CMS's NADAC survey (data as of Sep 30, 2026). This is a supply-cost benchmark — not a retail price and not what you'd pay at the counter.
| Form | Strength | Pharmacy acquisition benchmark | |
|---|---|---|---|
| Capsule | 1.25 mg | $0.080 per capsule | NDC details & price history |
| Capsule | 2.5 mg | $0.047 per capsule | NDC details & price history |
| Capsule | 5 mg | $0.051 per capsule | NDC details & price history |
| Capsule | 10 mg | $0.071 per capsule | NDC details & price history |
Source: CMS National Average Drug Acquisition Cost (NADAC), a survey of retail pharmacy invoice prices. Benchmarks shown are the range across package sizes of a representative product for each form and strength — other manufacturers' products may differ.
Ramipril brand names
Ramipril is sold under 2 brand names in the FDA directory — Altace, Vostally. A brand and its generic contain the same active ingredient; the brand name belongs to one company's product.
Who makes Ramipril: manufacturers and labelers
17 companies list Ramipril products with the FDA. By number of product records, the largest are A-S Medication Solutions, Northwind Health Company, LLC, Proficient Rx LP. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.
Ramipril drug class (RxNorm)
Ramipril belongs to the Angiotensin Converting Enzyme Inhibitor class.
Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.
Sources for this Ramipril page
Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.
How this page is built
HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. GSMS, Incorporated is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →